Gregory Demopulos, M.D. is President, CEO, Chairman and founder of Omeros Corporation (NASDAQ:OMER), a biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflammation, immunologic diseases and neurological disorders and a constituent of the NASDAQ Biotechnology and Russell 2000 Indexes. Dr. Demopulos completed his orthopedic surgery residency at Stanford University and his hand and microvascular surgery fellowship at Duke University. He received his M.D. and B.S. from Stanford University.
Dr. Demopulos serves as an Independent Trustee of the Smead Funds Trust, an open-end mutual fund company, and as a member of the Seattle Community Development Round Table. He has published numerous articles in peer-reviewed journals and is a named inventor on over 450 issued and pending U.S. and international patents.